Skip to content

ClearPoint Neuro CLPT Earnings yield

Earnings yield at other companies

Abbott logo
AbbottABT
3.5%-2.4pp
Boston Scientific logo
Boston ScientificBSX
3.8%+2.5pp
IAR
Integra LifeSciencesIART
-67.5%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
4.3%+0.2pp
Medtronic logo
MedtronicMDT
4.6%+0.3pp
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-13%-3.9pp

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$538.61M+69.2%
Enterprise value$565.68M+82.9%
P/S13.3×+3.4×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Calculated from ClearPoint Neuro’s reported figures.

Based on trailing twelve months.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ClearPoint Neuro's earnings yield?
ClearPoint Neuro (CLPT) reported earnings yield of -10.8% in Q1 2026.
How has ClearPoint Neuro's earnings yield changed year-over-year?
ClearPoint Neuro's earnings yield decreased by 70.1% year-over-year, from -6.3% to -10.8%.
What is the long-term trend for ClearPoint Neuro's earnings yield?
Over 5 years (2020 to 2025), ClearPoint Neuro's earnings yield has grown at a 28.3% compound annual growth rate (CAGR), from -1.8% to -6.3%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.